New anticoagulant therapy.

The development of new anticoagulants is expanding the list of drugs that can be used to prevent and treat venous and arterial thrombosis. New parenteral anticoagulants have been developed to overcome the limitations of heparin and low-molecular-weight heparin, whereas novel orally active anticoagulants have been designed to provide more streamlined therapy than vitamin K antagonists. This review identifies the molecular targets of new anticoagulants, describes the results of clinical trials, and provides clinical perspective on the opportunities for new anticoagulants.

[1]  G. Pineo,et al.  A Phase II Randomized, Double-Blind, Eight-Arm, Parallel-Group, Dose-Response Study of Apixaban, a New Oral Factor Xa Inhibitor for the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery - On Behalf of the Apixaban Investigators. , 2006 .

[2]  J. Douketis,et al.  Dose–response study of recombinant human soluble thrombomodulin (ART‐123) in the prevention of venous thromboembolism after total hip replacement , 2005, Journal of thrombosis and haemostasis : JTH.

[3]  G. Raskob,et al.  Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis , 2004, Annals of Internal Medicine.

[4]  V. Hasselblad,et al.  Initial experience with factor‐Xa inhibition in percutaneous coronary intervention: the XaNADU‐PCI Pilot , 2004, Journal of thrombosis and haemostasis : JTH.

[5]  Persist investigators.  A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation , 2004, Journal of thrombosis and haemostasis : JTH.

[6]  B. Eriksson,et al.  New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. , 2003, Chest.

[7]  B. Eriksson,et al.  The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study , 2003, Journal of thrombosis and haemostasis : JTH.

[8]  S. Olsson,et al.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial , 2003, The Lancet.

[9]  C. Colwell,et al.  Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. , 2003, The New England journal of medicine.

[10]  S. Schulman,et al.  Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.

[11]  M Gent,et al.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.

[12]  C. Colwell,et al.  Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double‐blind study , 2003, Journal of thrombosis and haemostasis : JTH.

[13]  D. Gustafsson.  Oral direct thrombin inhibitors in clinical development , 2003, Journal of internal medicine.

[14]  W. Weaver,et al.  Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial , 2003, The Lancet.

[15]  J. Halperin,et al.  Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). , 2003, American heart journal.

[16]  C. Sprung,et al.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. , 2003, JAMA.

[17]  B. Eriksson,et al.  Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. , 2003, Archives of internal medicine.

[18]  P. Petersen,et al.  Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation , 2003 .

[19]  H. Brogren,et al.  Quantification of ADP and ATP receptor expression in human platelets , 2003, Journal of thrombosis and haemostasis : JTH.

[20]  S. Schulman,et al.  A randomized, controlled, dose‐guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I , 2003, Journal of thrombosis and haemostasis : JTH.

[21]  C. Colwell,et al.  Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur , 2003 .

[22]  R. Peters,et al.  Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers , 2002, Circulation.

[23]  B. Eriksson,et al.  Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial , 2002, The Lancet.

[24]  P. Prandoni,et al.  Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. , 2002, Archives of internal medicine.

[25]  Dennis Mungall.  BIBR-1048 Boehringer Ingelheim. , 2002, Current opinion in investigational drugs.

[26]  J. Ferguson.  Meeting Highlights American Heart Association Scientific Sessions 2001 , 2002 .

[27]  R. Postier,et al.  Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study , 2001, Critical care medicine.

[28]  F. Van de Werf,et al.  A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. , 2001, European heart journal.

[29]  J. Douketis,et al.  Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials , 2001, The Lancet.

[30]  G. Raskob,et al.  Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement , 2001, Circulation.

[31]  A. Cohen,et al.  Extended Thromboprophylaxis with Low Molecular Weight Heparin Reduces Symptomatic Venous Thromboembolism following Lower Limb Arthroplasty - a Meta-analysis , 2001, Thrombosis and Haemostasis.

[32]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[33]  A Abrahamsson,et al.  The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.

[34]  M. Rafferty,et al.  An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. , 2000, Blood.

[35]  C. Francis,et al.  Low-molecular-weight heparin prophylaxis using dalteparin Extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients : A double-blind, randomized comparison , 2000 .

[36]  C. E. Ettingshausen,et al.  Replacement Therapy with Protein C Concentrate in Infants and Adolescents with Meningococcal Sepsis and Purpura Fulminans , 1999, Seminars in thrombosis and hemostasis.

[37]  J. Herbert,et al.  Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. , 1998, Blood.

[38]  Steven H. Huang,et al.  Anticoagulant repertoire of the hookworm Ancylostoma caninum. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  F. Taylor,et al.  Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. , 1996, Haemostasis.

[40]  J. Necciari,et al.  Pharmacokinetics and Tolerance of the Natural Pentasaccharide (SR90107/ORG31540) with High Affinity to Antithrombin III in Man , 1995, Thrombosis and Haemostasis.

[41]  E. Topol,et al.  Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. , 1995, Circulation.